Loading provider…
Loading provider…
Infectious Disease Physician in Philadelphia, PA
NPI: 1265571152Primary Employer
Philadelphia Fight
fight.org
HQ Phone
Get MD Karam's Phone Numberphone_androidMobile
Get MD Karam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
PA State Medical License
1995 - 2026
NJ State Medical License
1995 - 2005
DE State Medical License
1997 - 2003

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Infectious Disease
Cooper Medical School of Rowan University/Cooper University Hospital
Fellowship • Infectious Disease
1995 - 1997
Residency • Internal Medicine
1992 - 1995
St Joseph's University Medical School
Medical School
Until 1992
Authors: Tembeni, Babalwa, Sciorillo, Amanda, Invernizzi, Luke, Klimkait, Thomas, Urda, Lorena, Moyo, Phanankosi, Naidoo-Maharaj, Dashnie, Levitties, Nathan, Gyampoh, Kwasi, Zu, Guorui, Yuan, Zhe, Mounzer, Karam, Nkabinde, Siphathimandla, Nkabinde, Magugu, Gqaleni, Nceba, Tietjen, Ian, Montaner, Luis J, Maharaj, Vinesh
Journal: Viruses
Publication Date: 2022-06-30
Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.
Authors: Bonnie Howell, Pablo Tebas, Jay Kostman
Publication Date: 2020-12-16
Authors: Jay Kostman
Journal: J Immunol
Lead Sponsor: ViiV Healthcare
Collaborators: Janssen, LP
Intervention / Treatment: DRUG: Cabotegravir Tablets, DRUG: Rilpivirine Tablets, DRUG: Cabotegravir Injectable Suspension (CAB LA), DRUG: Rilpivirine Injectable Suspension (RPV LA), DRUG: BIKTARVY Tablets (BIK)
Lead Sponsor: ViiV Healthcare
Collaborators: GlaxoSmithKline
Intervention / Treatment: DRUG: DTG + 3TC, DRUG: TAF based regimen (TBR)
Lead Sponsor: Luis Montaner
Collaborators: Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID), University of Pennsylvania, Rockefeller University, Philadelphia Fight
Intervention / Treatment: DRUG: 3BNC117 + 10-1074, DRUG: Pegylated Interferon alpha 2b (peg-IFN-α2b)